乳腺癌患者手术前后血清可溶性白细胞介素-2受体水平的变化

INVESTIGATION OF PREOPERATIVE AND POSTOPERATIVE SERUM SOLUBLE INTERLEUKIN 2 RECEPTOR IN PATIENTS WITH BREAST CANCER

为探讨血清可溶性白细胞介素２ 受体（ｓ Ｉ Ｌ２ Ｒ）水平与乳腺癌的分期和预后的关系，采用 Ｅ Ｌ Ｉ Ｓ Ａ 法对 ３７ 例乳腺癌患者手术前后血清 ｓ Ｉ Ｌ２ Ｒ 进行检测，同期检测了 １３ 例乳腺良性疾病患者及 ４０ 例正常人血清 ｓ Ｉ Ｌ２ Ｒ水平。结果： 乳腺癌患者血清ｓ Ｉ Ｌ２ Ｒ明显高于乳腺良性疾病组和正常对照组，其术后 ２０ 天血清 ｓ Ｉ Ｌ２ Ｒ水平明显低于术前； 乳腺癌患者血清 ｓ Ｉ Ｌ２ Ｒ水平与临床分期密切相关，Ⅲ期患者明显高于Ⅰ、Ⅱ期，且术后 ２０ 天仍保持在较高水平上。由此提示，血清 ｓ Ｉ Ｌ２ Ｒ 的表达水平与乳腺癌患者的临床分期和预后密切相关，可作为鉴别乳腺良恶性疾病的一项参考指标。

To investigate the relationship between the serum soluble interleukin 2 receptor (sIL 2R) and the stage and prognosis of breast cancer. Using the method of sandwich ELISA, the preoperative and postoperative sIL 2R in 37 cases of breast cancer was measured, 13 patients with benign disease of breast and 40 normals were also measured. The serum sIL 2R levels in patients with breast cancer were significantly higher than that of the benign disease of breast and the normal controls. The serum sIL 2R about twenty days after operation was significantly lower than that before operation. The sIL 2R in patients with breast cancer was correlative to the clinical stage. The serum sIL 2R in stage Ⅲ patients was remarkly higher than both stage Ⅰ and Ⅱ, its sIL 2R about twenty days after operation remained in a high level. This results showed that expression of the serum sIL 2R is correlative to the clinical stage and prognosis of the patients with breast cancer, it can be used as a marker of differentiating the benign from malignant disease of breast.